Takeda Ventures Inc.

Takeda Ventures Inc. is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, established in 2001 to invest in early-stage, preclinical therapeutic platform opportunities that complement Takeda's pipeline. The firm focuses on high-caliber, therapeutic, platform-based companies worldwide, aiming to create strategic growth opportunities for Takeda by building, managing, and investing in innovative life science companies.

The investment strategy of Takeda Ventures aligns with Takeda's R&D pillars, including Oncology, Rare Genetics & Hematology, Neuroscience, and Gastrointestinal and Inflammation. By partnering with academic innovators, entrepreneurs, and venture investors, Takeda Ventures seeks to support therapeutic innovation and provide access to the resources of a multinational pharmaceutical company. The firm emphasizes collaborative interactions that result in synergies with Takeda's considerable R&D resources.

Takeda Ventures has a track record of investing in companies such as CellCentric, Symphogen, and Xenon Pharmaceuticals, reflecting its commitment to supporting innovative ventures in the healthcare sector. The firm operates globally, with offices in locations such as Palo Alto, California, and Cambridge, Massachusetts, and maintains a strong presence in Japan, Europe, and other regions.

For more information or to explore potential investment opportunities, interested parties can contact Takeda Ventures via email at TVI@takeda.com. Please note that nothing in the website is intended to constitute an offer of any kind, a guarantee of investment, or an obligation to enter into discussions with any party on behalf of Takeda Ventures, Inc., Takeda Pharmaceutical Company Limited, or any affiliate or subsidiary.

Please be aware that Takeda Ventures' investment focus and portfolio may evolve over time. For the most current information, it is advisable to visit their official website or contact them directly.